Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-02-06T04:19:33.458Z Has data issue: false hasContentIssue false
  • English
  • Français

Aripiprazole-Related Tardive Dyskinesia

Published online by Cambridge University Press:  07 November 2014

Guy Maytal ,
Michael Ostacher  and
Theodore A. Stern
Get access Rights & Permissions [Opens in a new window]

Abstract

The low prevalence of extrapyramidal symptoms associated with atypical antipsychotics has led to their widespread use during the past decade. Aripiprazole, the newest medication in this class, has been associated with extrapyramidal symptoms (eg, akathisia) and with improvement of tardive dyskinesia (TD), but to date it has not been associated with the development of TD. We report a case of TD associated with the use of aripiprazole 15 mg/day for 18 months for refractory depression. Symptoms of TD resolved within several weeks of discontinuation of aripiprazole.

Type
Case Report
Information
CNS Spectrums , Volume 11 , Issue 6 , June 2006 , pp. 435 - 439
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Matza, LS, Baker, TM, Revicki, DA. Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review. CNS Drugs. 2005:19:499–515.Google Scholar
2.Hargreaves, WA, Gibson, JP. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs. 2005:19:393–410.CrossRefGoogle ScholarPubMed
3.Thase, ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry. 2002;63:95–103.Google Scholar
4.Kane, J. Tardive dyskinesia rates with atypical antipsychotics In adults: prevalence and Incidence. J Clin Psychiatry. 2004;65(suppl 9):16–20.Google Scholar
5.Pierre, JM. Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention and management. Drug Saf 2005;28:191–208.Google Scholar
6.Witschy, JK, Winter, AS. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry. 2005;50:188.Google Scholar
7.Duggal, HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry. 2003;48:771–772.Google Scholar
8.Fogel, BS, Schiffer, RB, Rao, SM, eds. Neuropsychiatry. Baltimore, Md: Williams & Wilkins: 1996.Google Scholar
9.Hyman, SE, Arana, GW, Rosenbaum, JF, eds. Handbook of Psychiatric Drug Therapy. 3rd ed. Boston, Mass Little Brown and Company: 1995:35–37.Google Scholar
10.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
11.Sadock, BJ, Sadock, VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia, Penn: Lippincott Williams & Wilkins; 2000.Google Scholar
12.Aparasu, RR, Bhatara, V, Gupta, S. U.S. national trends in the use of antipsychotics during office visits, 1998-2002. Ann Clin Psychiatry. 2005;17:147–152.CrossRefGoogle ScholarPubMed
13.Cooper, WO, Arbogast, PG, Ding, H, Hickson, GB, Fuchs, DC, Ray, WA. Trends In prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6:79–83.Google Scholar
14.Glick, ID, Murray, SR, Vasudevan, P, Marder, SR, Hu, RJ. Treatment with atypical antipsychotics: new Indications and new populations. JPsychiatr Res. 2001;35:187–191.Google Scholar
15.Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414–425.Google Scholar
16.Margolese, HC, Chouinard, G, Kolivakis, TT, Beauclair, L, Miller, R, Annable, L. Tardive dyskinesia In the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies In patients with schizophrenia. Can J Psychiatry. 2005;50:703–714.Google Scholar
17.Nasrallah, HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry. 2006;18:57–62.Google Scholar
18.Tarsy, D, Baldessarini, RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord. 2006;10:[Epub ahead of print].Google Scholar
19.Carpenter, WT Jr, Bartko, JJ, Carpenter, CL, Strauss, JS. Another view of schizophrenia subtypes. A report from the International pilot study of schizophrenia. Arch Gen Psychiatry. 1976;33:508–516.Google Scholar
20.Alexopoulos, GS. Lack of complaints in schizophrenics with tardive dyskinesia. J Nerv Ment Dis. 1979;167:125–127.Google Scholar
21.Myslobodsky, MS, Tomer, R, Holden, T, Kempler, S, Sigal, M. Cognitive Impairment In patients with tardive dyskinesia. J Nerv Ment Dis. 1985;173:156–160.CrossRefGoogle ScholarPubMed
22.Arango, C, Adami, H, Sherr, JD, Thaker, GK, Carpenter, WT Jr.Relationship of awareness of dyskinesia In schizophrenia to insight into mental illness. Am J Psychiatry. 1999;156:1097–1099.Google Scholar
23.Blanchet, PJ, Rompre, PH, Lavigne, GJ, Lamarche, C. Oral dyskinesia: a clinical overview. Int J Prosthodont. 2005;18:10–19.Google Scholar
24.Schatzberg, AF, Nemeroff, CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995:626–628.Google Scholar
25.Tarsy, D, Baldessarini, RJ, Tarazi, FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16:23–45.Google Scholar
26. Bristol-Meyers Squibb product Information for Abilify (aripiprazole). Available at: http://www.bms.com/cgl-bin/anybln.pI?sql=select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=101&key=PPI. Accessed on April 4, 2006.Google Scholar
27.Witschy, JK, Winter, AS. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry. 2005;50:188.Google Scholar
28.Sharma, A, Ramaswamy, S, Dewan, VK. Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry. 2005;7:36.Google Scholar